Funded Biotechnology Startups in St Louis
11 funded biotechnology startups in st louis — recent funding rounds, disclosed amounts, and headquarters. Updated weekly, free to browse.
The largest disclosed round among the 11 St. Louis biotechnology entries is Wugen’s $115M on 2025-08-27. That amount is a clear outlier compared with the rest of the disclosed figures, where only Varro’s $7M (2025-10-20) sits above $5M and the remaining disclosed rounds fall at $3M or $2M (e.g., Omniose $3M on 2023-09-27; BioSTL $2M on 2020-09-16), with multiple records marked “undisclosed.”
The dataset is also clustered temporally: five of the 11 rows are dated 2023 or later, spanning from BioSTL’s 2020-09-16 to the most recent Varro entry on 2025-10-20. By classification, “Series Unknown” appears in 7 of the 11 rows, and “undisclosed” appears in 3 rows (BIOIO on 2024-02-06; HIVE Medical and InterShunt, both on 2023-06-06), shaping how much comparability the list supports at a deal-size level.
Most recent rounds
11 shownRelated listings
Frequently asked
What’s the biggest disclosed round in this St. Louis biotech list, and how does it stack up against other disclosed amounts?
Wugen’s $115M (2025-08-27) dwarfs the disclosed set: beyond it, the next-highest disclosed figure is Varro’s $7M (2025-10-20), while Omniose posts $3M (2023-09-27) and BioSTL is $2M (2020-09-16).
Do deal sizes concentrate in a narrow band, or are there notable outliers besides Wugen?
Disclosed amounts are clustered at the low single-digit to teens range, including Panome Bio’s $6M (2024-11-21) and Mazen Animal Health’s $11M (2022-05-25). The main outlier remains Wugen’s $115M on 2025-08-27, while three entries instead show “undisclosed” (BIOIO 2024-02-06; HIVE Medical and InterShunt 2023-06-06).
Which entries fall in the most recent 90 days shown, based on the round dates?
Using the latest date in the list (Varro on 2025-10-20), the rows in the preceding ~90 days include Varro (2025-10-20, $7M), GenAssist (2025-10-17, $80K), and Wugen (2025-08-27, $115M).
How much of the list is hard to compare due to missing or non-specific round information (Series Unknown vs undisclosed amounts)?
“Series Unknown” covers 7 of 11 rows, including Varro (2025-10-20, $7M) and GenAssist (2025-10-17, $80K). Separately, 3 rows carry “undisclosed” amounts (BIOIO 2024-02-06; HIVE Medical 2023-06-06; InterShunt 2023-06-06), reducing confidence in any deal-size ranking that includes them.
Does any stage label dominate, or do stages look spread across entries with one or two “anchor” companies?
Stage labels appear limited rather than evenly distributed: Series Unknown is most common (7/11), while specific disclosed stages include Wugen as Series C ($115M on 2025-08-27), Mazen Animal Health as Series A ($11M on 2022-05-25), and PierianDx as “Venture - Series Unknown” ($30M on 2021-11-02).
Are there any concentration patterns in dates or clusters that stand out relative to the 2020–2025 range?
There’s a tight multi-entry moment in mid-2023: HIVE Medical and InterShunt both close on 2023-06-06 (amounts undisclosed). More broadly, five entries are dated 2023 or later, spanning from Omniose (2023-09-27, $3M) through Varro (2025-10-20, $7M).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.